Structure-Based Design of MptpB Inhibitors That Reduce Multidrug-Resistant Mycobacterium tuberculosis Survival and Infection Burden in Vivo

Authors:

Abstract
Mycobacterium tuberculosis protein-tyrosine-phosphatase B (MptpB) is a secreted virulence factor that subverts antimicrobial activity in the host. We report here the structure-based design of selective MptpB inhibitors that reduce survival of multidrug-resistant tuberculosis strains in macrophages and enhance killing efficacy by first-line antibiotics. Monotherapy with an orally bioavailable MptpB inhibitor reduces infection burden in acute and chronic guinea pig models and improves the overall pathology. Our findings provide a new paradigm for tuberculosis treatment.
Funding Information
  • Medical Research Council (G0701233, FC001092, MC_UP_1202/11)
  • Francis Crick Institute
  • Ministerio de Economía y Competitividad (BIO2016-78006-R)
  • Agència de Gestió d'Ajuts Universitaris i de Recerca (2009PIV 00100)
  • National Institute of Allergy and Infectious Diseases (U19AI109713)
  • Wellcome (FC001092)
  • Biotechnology and Biological Sciences Research Council
  • Cancer Research UK (FC001092)
  • Manchester Chemical Biology Network

This publication has 37 references indexed in Scilit: